Breaking News Instant updates and real-time market news.

PCRX

Pacira

$33.30

3.8 (12.88%)

, HRTX

Heron Therapeutics

$26.75

-1.15 (-4.12%)

06:05
04/09/18
04/09
06:05
04/09/18
06:05

Piper reiterates Overweight on Pacira after 'watershed' nerve block approval

FDA approval of Pacira Pharmaceuticals' (PCRX) Exparel as a brachial plexus block "is something of a watershed" in that the agency has never before approved any local or regional anesthetic for a single, specific setting, Piper Jaffray analyst David Amsellem tells investors in a research note. He believes the approval suggests an increasingly aggressive FDA approach towards the opioid crisis. Amsellem points out, however, that feedback from his surgeon survey suggests a "strong degree of enthusiasm" for Heron Therapeutics' (HTRX) HTX-011. However, the feedback also indicates that non-opioid, post-operative pain space is not a zero-sum game, the analyst writes. He believes Exparel can grow "even amid greater competition." Amsellem reiterates an Overweight rating on Pacira with a $44 price target.

PCRX

Pacira

$33.30

3.8 (12.88%)

HRTX

Heron Therapeutics

$26.75

-1.15 (-4.12%)

  • 16

    Apr

  • 08

    May

PCRX Pacira
$33.30

3.8 (12.88%)

03/19/18
JEFF
03/19/18
NO CHANGE
Target $30
JEFF
Buy
Heron pain drug 'hits a home run' in Phase III studies, says Jefferies
Jefferies analyst Biren Amin says Heron Therapeutics's (HRTX) HTX-011 "hits a home run" by meeting all primary and key secondary endpoints this morning from Phase III trials in bunionectomy and hernia repair. Safety looked clean in both studies, and HTX-011 produced durable pain reduction up to 72 hours and significant opioid sparing effect and differentiates from generic bupivacaine, Amin tells investors in a research note. The analyst believes HTX-011 should receive a superiority claim versus generic bupivacaine in its label for both bunionectomy and hernia surgery. Amin notes that Pacira's (PCRX) Exparel does not have this claim in its label. He assumes peak sales of $545M for HTX-011 and keeps a Buy rating on Heron with $30 price target.
03/20/18
GHSC
03/20/18
NO CHANGE
Target $42
GHSC
Buy
Pacira price target lowered to $42 after Heron data at Seaport Global
Seaport Global analyst Corey Davis noted that Heron Therapeutics (HRTX) reported positive results from its two Phase 3 studies of HTX-011 for postoperative pain in bunionectomy and herniorrhaphy. While Heron's HTX-011 data suggest some competition in 2020 for Pacira's (PCRX) Exparel, Davis said dose and volume "present problems" and that Heron "may run into a pricing problem" as well. He reiterates his Buy rating on Pacira shares, though he lowered his price target on the stock to $42 from $50, noting that he has formally removed nerve block revenue for Exparel entirely from his model after the negative FDA AdCom last month.
03/21/18
JEFF
03/21/18
NO CHANGE
Target $49
JEFF
Buy
Pacira shares could be positioned for rebound, says Jefferies
Jefferies analyst David Steinberg believes shares of Pacira Pharmaceuticals could be positioned for a rebound after Symphony Health data indicated Exparel posted "well above trend growth" in February. Sales were $24M, up 3.4% from last month and up 12.6% year-over-year, according to Symphony. The data have shown double digit year-over-years gains in four of the past five months, versus just one of nine months prior, Steinberg tells investors in a research note. He believes Pacira is attractively valued at current levels and keeps a Buy rating on the shares with a $49 price target.
04/06/18
WEDB
04/06/18
NO CHANGE
Target $72
WEDB
Outperform
Wedbush says FDA response for Pacira's EXPAREL in nerve block due
Wedbush analyst Liana Moussatos reiterated an Outperform rating and $72 price target on Pacira Pharmaeuticals ahead of the expected PDUFA date for potential expansion of EXPAREL's label to specify nerve block. In a research note to investors, the analyst said she is "hopeful" that EXPAREL could potentially be used to provide improved outcomes in long-acting regional analgesia compared to infusion pumps or opioids. Whether required post-approval or in preparation for future regulatory review, she sees Pacira to continuing to evaluate EXPAREL in different nerve block techniques.
HRTX Heron Therapeutics
$26.75

-1.15 (-4.12%)

03/20/18
NEED
03/20/18
NO CHANGE
Target $42
NEED
Buy
Heron Therapeutics price target raised to $42 from $30 at Needham
Needham analyst Serge Belanger raised his price target on Heron Therapeutics to $42 after the company's phase 3 trial results for HTX-011 on post-surgical pain management. The analyst says the treatment met all the primary and secondary endpoints while also demonstrating superiority over placebo and bupivacaine in terms of pain relief and opioid consumption. Belanger keeps his Buy rating on Heron Therapeutics, adding that the HTX-011 could be "game changer", with NDA filing coming in the second half of this year.
04/05/18
LSCM
04/05/18
NO CHANGE
Target $42
LSCM
Buy
Heron 'ready for liftoff' after secondary offering, says Lake Street
Lake Street analyst Bruce Jackson updated his model for Heron Therapeutics following the recently completed stock offering. In a research note partially titled, "Fuel Tank Filled, Ready For Lift Off," the analyst reiterates a Buy rating on Heron with a $42 price target. New Phase 3 data for HTX-011 demonstrated statistically significant reductions in pain intensity and opioid use through 72 hours post-surgery compared to placebo and the current standard of care, bupivacaine, Jackson writes. He notes that management believes the data support an opioid-sparing labeling claim for HTX-011. This would provide a significant competitive advantage, the analyst contends.
04/05/18
EVER
04/05/18
INITIATION
Target $56
EVER
Outperform
Heron Therapeutics initiated with an Outperform at Evercore ISI
Evercore ISI analyst Joshua Schimmer started Heron Therapeutics (HRTX) with an Outperform rating and $56 price target. He said that given the marked differentiation versus Pacira's (PCRX) Exparel, peak sales for Heron's HTX-011 could approach $2.5B, while Sustol/Cinvanti could add another $300M at peak. These estimates could drive a valuation potentially approaching $11B, or nearly $175 per share, in a bullish scenario, said Schimmer.

TODAY'S FREE FLY STORIES

KRNY

Kearny Financial

$13.75

0.25 (1.85%)

18:02
09/19/18
09/19
18:02
09/19/18
18:02
Hot Stocks
Kearny Financial declares special cash dividend of 16c per share »

Kearny Financial has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVA

Avista

$51.50

0.01 (0.02%)

18:00
09/19/18
09/19
18:00
09/19/18
18:00
Hot Stocks
Avista, Hydro One extend merger end date »

Hydro One Limited and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,926.27

-14.93 (-0.77%)

17:57
09/19/18
09/19
17:57
09/19/18
17:57
Periodicals
Amazon leaks new Alexa smart plug and a subwoofer, Verge says »

According to the Verge,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$163.06

2.75 (1.72%)

17:45
09/19/18
09/19
17:45
09/19/18
17:45
Periodicals
Facebook sets up 'War Room' for safeguarding elections, NY Times says »

After Facebook gained…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

RRTS

Roadrunner

$1.16

-0.065 (-5.33%)

17:45
09/19/18
09/19
17:45
09/19/18
17:45
Syndicate
Roadrunner files S-1 for rights offering to existing holders »

Roadrunner announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASB

Associated Banc-Corp

$26.45

0.3 (1.15%)

17:35
09/19/18
09/19
17:35
09/19/18
17:35
Hot Stocks
Associated Banc-Corp announces $200M share repurchase program »

Associated's Board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLIN

Bridgeline Digital

$1.02

-0.01 (-0.98%)

17:32
09/19/18
09/19
17:32
09/19/18
17:32
Syndicate
Breaking Syndicate news story on Bridgeline Digital »

Bridgeline Digital files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NGD

New Gold

$1.10

0.03 (2.80%)

17:29
09/19/18
09/19
17:29
09/19/18
17:29
Hot Stocks
New Gold sells Mesquite Mine to Eqiunox Gold for $158M »

New Gold has entered into…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$291.22

0.26 (0.09%)

17:23
09/19/18
09/19
17:23
09/19/18
17:23
Periodicals
Trudeau wants to see more U.S. flexibility around NAFTA, Reuters says »

Canadian prime minister…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$291.22

0.26 (0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$339.26

-3.94 (-1.15%)

17:18
09/19/18
09/19
17:18
09/19/18
17:18
Hot Stocks
Lockheed Martin awarded $132.3M U.S. Navy contract modification »

Lockheed Martin Rotary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHT

Red Hat

$143.38

0.59 (0.41%)

17:17
09/19/18
09/19
17:17
09/19/18
17:17
Hot Stocks
Breaking Hot Stocks news story on Red Hat »

Red Hat CFO sees FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

ELAN

Elanco

$0.00

(0.00%)

17:14
09/19/18
09/19
17:14
09/19/18
17:14
Syndicate
Elanco 62.9M share IPO priced at $24.00 »

The IPO priced above its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

MAMS

MAM Software

$7.67

0.02 (0.26%)

17:10
09/19/18
09/19
17:10
09/19/18
17:10
Hot Stocks
MAM Software announces $2M share repurchase program »

MAM Software Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTC

Bitcoin

$0.00

(0.00%)

, BITCOIN

Bitcoin

$0.00

(0.00%)

17:08
09/19/18
09/19
17:08
09/19/18
17:08
Hot Stocks
Coinbase names Brian Brooks chief legal officer »

Coinbase said in a blog…

BTC

Bitcoin

$0.00

(0.00%)

BITCOIN

Bitcoin

$0.00

(0.00%)

FNMA

Fannie Mae

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHT

Red Hat

$143.38

0.59 (0.41%)

17:07
09/19/18
09/19
17:07
09/19/18
17:07
Hot Stocks
Breaking Hot Stocks news story on Red Hat »

Red Hat CEO says he…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

RHT

Red Hat

$143.38

0.59 (0.41%)

17:06
09/19/18
09/19
17:06
09/19/18
17:06
Hot Stocks
Breaking Hot Stocks news story on Red Hat »

Red Hat says 24 of its 25…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

RHT

Red Hat

$143.38

0.59 (0.41%)

17:05
09/19/18
09/19
17:05
09/19/18
17:05
Hot Stocks
Red Hat Q2 backlog was up 20% on the year »

Deals over $1M were up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

RRTS

Roadrunner

$1.16

-0.065 (-5.33%)

17:01
09/19/18
09/19
17:01
09/19/18
17:01
Syndicate
Breaking Syndicate news story on Roadrunner »

Roadrunner files $450M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RYAM

Rayonier Advanced Materials

$21.39

0.165 (0.78%)

16:58
09/19/18
09/19
16:58
09/19/18
16:58
Hot Stocks
Rayonier Advanced Materials sells resins business to LRBG Chemicals for $16.5M »

Rayonier Advanced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

UNIT

Uniti Group

$20.82

-0.1 (-0.48%)

16:57
09/19/18
09/19
16:57
09/19/18
16:57
Hot Stocks
Uniti Group completes sale-leaseback and fiber acquisition with U.S.TelePacific »

Uniti Group announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LBTYA

Liberty Global

$28.59

0.32 (1.13%)

, LBTYK

Liberty Global

$27.62

0.35 (1.28%)

16:57
09/19/18
09/19
16:57
09/19/18
16:57
Conference/Events
Liberty Global management to meet with Evercore ISI »

Group Luncheon Meeting to…

LBTYA

Liberty Global

$28.59

0.32 (1.13%)

LBTYK

Liberty Global

$27.62

0.35 (1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 28

    Sep

  • 28

    Sep

HEAR

Turtle Beach

$19.19

1.44 (8.11%)

16:54
09/19/18
09/19
16:54
09/19/18
16:54
Hot Stocks
Breaking Hot Stocks news story on Turtle Beach »

Vinik Family Investments…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRC

Nac Re

$38.10

-1.25 (-3.18%)

16:54
09/19/18
09/19
16:54
09/19/18
16:54
Hot Stocks
National Research director Donald Berwick sells 17K shares of company stock »

National Research…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGA

Magna

$54.44

0.805 (1.50%)

16:53
09/19/18
09/19
16:53
09/19/18
16:53
Conference/Events
Magna management to meet with Evercore ISI »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

NVCR

Novocure

$52.05

3.05 (6.22%)

16:51
09/19/18
09/19
16:51
09/19/18
16:51
Conference/Events
Novocure management to meet with Evercore ISI »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.